Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The source introductory threshold is rendered =60; the source table is preserved separately. This is not a newly verified label transcription.
Check source scope before reading a dose
Stanford - cefepime dialysis strategies
Product / population
Adults; cefepime IV. Guide page 2, IHD/CRRT columns.
Renal method
IHD assumes three sessions weekly; CRRT-specific column.
Source revision
Current retrieved guide; see source document for revision history.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Daily post-HD timing is not the same as post-HD-only dosing
Label and institutional sources include daily dosing and post-dialysis-only schedules. Their indication, dialysis frequency, infusion, and exposure assumptions differ.
What to reconcile: Select one complete locally approved regimen; do not add a daily dose on top of a post-HD-only schedule.
Source difference identified; final patient-specific adjudication required.
Stanford Health Care Antimicrobial Safety and Sustainability · Adults; cefepime IV. Guide page 2, IHD/CRRT columns.
Renal method: IHD assumes three sessions weekly; CRRT-specific column. Source date: Current retrieved guide; see source document for revision history. Retrieved: 2026-09-05
Locally included source-specific summary. Regimen differences are not automatically resolved.
Dosing / renal protocol and limits
In the Stanford guide, IHD dosing is 0.5-1 g IV daily, after HD on treatment days; 2 g after each HD session is an alternative. CRRT uses a 2 g load followed by 1 g every 8 hours as a 4-hour infusion. These are separate dialysis options, not additive doses.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.